Literature DB >> 13954

Altered hepatic blood flow and drug disposition.

A S Nies, D G Shand, G R Wilkinson.   

Abstract

For some drugs, delivery to the liver by the hepatic circulation is an important determinant of removal by this organ. Classical pharmacokinetic analyses cannot predict the changes produced by altering any of the biological determinants of drug elimination by the liver; hepatic blood flow, metabolic enzyme activity, drug binding and route of administration. However, with the use of a physiological model of hepatic drug elimination, such predictions can be made. This model has been tested experimentally and appears to be valid. Hepatic blood flow can vary over about a 4-fold range from half normal flow to twice logical changes affecting the circulation. For drug clearance to be affected significantly by these changes in flow, the drug must be avidly removed by the liver as reflected in a high hepatic extraction ratio and intrinsic hepatic clearance. This latter term is a useful way to characterise the ability of the liver to irreversibly remove drug from the circulation in the absence of any flow limitation. The clearance of drugs with low intrinsic clearance will not be affected significantly by changes in liver blood flow.

Mesh:

Substances:

Year:  1976        PMID: 13954     DOI: 10.2165/00003088-197601020-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  59 in total

1.  Liver blood flow and blood volume following chronic phenobarbitone administration.

Authors:  E E Ohnhaus; J T Locher
Journal:  Eur J Pharmacol       Date:  1975-04       Impact factor: 4.432

2.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

3.  The effect of adrenaline and noradrenaline on hepatic blood flow and splanchnic carbohydrate metabolism in man.

Authors:  A G BEARN; B BILLING; S SHERLOCK
Journal:  J Physiol       Date:  1951-12-28       Impact factor: 5.182

Review 4.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

Review 5.  Human cardiovascular adjustments to exercise and thermal stress.

Authors:  L B Rowell
Journal:  Physiol Rev       Date:  1974-01       Impact factor: 37.312

6.  Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man.

Authors:  A W Meikle; W Jubiz; S Matsukura; C D West; F H Tyler
Journal:  J Clin Endocrinol Metab       Date:  1969-12       Impact factor: 5.958

7.  Genetic control of drug levels and of the induction of drug-metabolizing enzymes in man: individual variability in the extent of allopurinol and nortriptyline inhibition of drug metabolism.

Authors:  E S Vesell; G T Passananti; F E Greene; J G Page
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

8.  Quinidine elimination in patients with congestive heart failure or poor renal function.

Authors:  K M Kessler; D T Lowenthal; H Warner; T Gibson; W Briggs; M M Reidenberg
Journal:  N Engl J Med       Date:  1974-03-28       Impact factor: 91.245

9.  Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey.

Authors:  R A Branch; D G Shand; A S Nies
Journal:  J Pharmacol Exp Ther       Date:  1973-12       Impact factor: 4.030

10.  The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver.

Authors:  R A Branch; A S Nies; D G Shand
Journal:  Drug Metab Dispos       Date:  1973 Sep-Oct       Impact factor: 3.922

View more
  66 in total

1.  Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.

Authors:  Charles S Venuto; Andrew H Talal
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

2.  Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers.

Authors:  Hua-Wen Xin; Xiao-Chun Wu; Qing Li; Ai-Rong Yu; Lei Xiong
Journal:  Br J Clin Pharmacol       Date:  2009-02-04       Impact factor: 4.335

3.  The analysis and disposition of imipramine and its active metabolites in man.

Authors:  T A Sutfin; C L DeVane; W J Jusko
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog.

Authors:  T Ishizaki; K Tawara
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

Review 5.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 6.  Drug interactions with thrombolytic agents. Current perspectives.

Authors:  A de Boer; J M van Griensven
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.

Authors:  H I Pirttiaho; E A Sotaniemi; R O Pelkonen; U Pitkänen; M Anttila; H Sundqvist
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

8.  Influence of physical exercise on the pharmacokinetics of propranolol.

Authors:  B G Arends; R O Böhm; J E van Kemenade; K H Rahn; M A van Baak
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of pethidine.

Authors:  L E Mather; P J Meffin
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.